ArticleLancet (London, England)2021

Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002).

Amy Flaxman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.